SYDNEY, June 3, 2021 /PRNewswire/ -- Kazia Therapeutics
Limited (NASDAQ: KZIA), an oncology-focused drug development
company, announced today that its CEO, Dr James Garner, will be presenting virtually at
the upcoming LD Micro Invitational XI.
Dr Garner commented, "this is a particularly exciting time for
Kazia, with our lead program, paxalisib, now well-advanced in a
pivotal study, and a promising new program, EVT801, due to enter
the clinic this year. We look forward to updating the attendees on
our progress, and on the rich slate of news flow anticipated for
the second half of the year."
Event:
|
Kazia Presentation at
the LD Micro Invitational XI
|
Date:
|
Wednesday 9 June
2021
|
Time:
|
5pm, Eastern
Time
|
Investors may register for free to attend the event by using the
following link:-
https://ldmicrojune2021.mysequire.com/
The 2021 LD Micro Invitational will be held on the Sequire
Virtual Events platform on Tuesday, June 8th
- Thursday, June 10th, 2021, running from 7:00 AM PT - 3:00 PM PT / 10:00 AM ET - 6:00 PM ET each day.
This three-day, virtual investor conference is expected to
feature around 180 companies, presenting for 25 minutes each, as
well as several influential keynotes. The first day of this
conference will also feature an exceptional one-time event: the LD
Micro Hall of Fame.
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Seven
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study is expected to begin in CY2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
About LD Micro
LD Micro (NASDAQ: SRAX) aims to be the most crucial resource in
the micro-cap world. Whether it is the index, comprehensive data,
or hosting the most significant events on an annual basis, LD's
sole mission is for the Texas Rangers to win the World Series and
serve as an invaluable asset for all those interested in finding
the next generation of great companies.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-ld-micro-invitational-xi-301304864.html
SOURCE Kazia Therapeutics Limited